| Oct 30 |
Blueprint Medicines: Q3 Earnings Snapshot
|
| Oct 30 |
Blueprint Medicines beats Q3 top and bottom-line estimates
|
| Oct 30 |
Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
|
| Oct 29 |
Blueprint Medicines Q3 2024 Earnings Preview
|
| Oct 27 |
Blueprint Medicines Corporation (NASDAQ:BPMC): Are Analysts Optimistic?
|
| Oct 25 |
Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma
|
| Oct 24 |
Regeneron (REGN) Earnings Expected to Grow: Should You Buy?
|
| Oct 23 |
Blueprint Medicines (BPMC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
|
| Oct 21 |
Blueprint Medicines (BPMC) Upgraded to Strong Buy: What Does It Mean for the Stock?
|
| Oct 16 |
Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024
|
